What are the indications for imeglimin in adults with type 2 diabetes mellitus?

Imeglimin Indications

Based on the available evidence, imeglimin is NOT indicated for type 2 diabetes mellitus in the United States or most Western countries. The FDA-approved drug labeled as "IGALMI" (which appears in the evidence) is actually dexmedetomidine sublingual film for acute agitation in schizophrenia or bipolar disorder—not imeglimin for diabetes 1.

Critical Clarification: Geographic Availability

Imeglimin is currently approved ONLY in Japan for the treatment of type 2 diabetes mellitus 2, 3, 4, 5. It is not FDA-approved in the United States, nor is it mentioned in any major international diabetes guidelines including the 2024-2025 ADA Standards of Care 6, 7, 6, the 2024 ACP guidelines 8, or the 2025 BMJ living guidelines 9.

Japanese Indication (Where Approved)

In Japan, imeglimin is indicated for:

• Adults with type 2 diabetes mellitus requiring glycemic control 2, 4, 5, 10, 11

Specific Clinical Contexts Supported by Evidence:

Primary use scenarios:

• As monotherapy or combination therapy when metformin is not tolerated (particularly gastrointestinal intolerance) 4
• Add-on therapy to DPP-4 inhibitors in patients with inadequate glycemic control 2
• In older adults (≥65 years), where it shows particular efficacy 2, 12
• In patients with renal dysfunction, including those on dialysis (at reduced doses: 500 mg/day) 3

Mechanism and Clinical Effects:

Imeglimin works through a unique mitochondrial mechanism targeting three key pathophysiologic defects in type 2 diabetes 5, 11:

1. Reduces hepatic gluconeogenesis
2. Enhances glucose-stimulated insulin secretion from pancreatic β-cells
3. Improves peripheral insulin sensitivity in skeletal muscle, liver, and adipose tissue

Expected glycemic improvements 2, 4, 10:

• HbA1c reduction: approximately 0.6-1.0% over 12-24 weeks
• Fasting plasma glucose reduction: ~30-35 mg/dL
• Postprandial glucose reduction: ~45 mg/dL

Dosing (Japanese Approval):

• Standard dose: 1000 mg orally twice daily (2000 mg/day total) 2, 4, 10, 11
• Renal impairment/dialysis: 500 mg/day 3
• Peak effect reached at 16 weeks 5

Safety Profile:

Favorable characteristics 2, 3, 4:

• Low hypoglycemia risk (only 1 mild case reported in clinical trials)
• Minimal gastrointestinal side effects (2% incidence)
• Weight neutral to modest weight loss (~0.8 kg reduction)
• Stable renal function in dialysis patients
• Well-tolerated in elderly patients

Important Caveats:

1. This medication is NOT available for prescription in the United States, Europe, or most other countries outside Japan
2. The FDA drug label evidence provided 1 refers to a completely different medication (dexmedetomidine for agitation), not imeglimin for diabetes
3. Major international diabetes guidelines do not include imeglimin in treatment algorithms because it lacks regulatory approval outside Japan
4. If you are practicing outside Japan, you cannot prescribe this medication—focus instead on guideline-recommended agents: metformin, SGLT-2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, or insulin 6, 7, 8, 9